Skip to content


  • Research article
  • Open Access
  • Open Peer Review

Long non-coding RNA MALAT-1 modulates metastatic potential of tongue squamous cell carcinomas partially through the regulation of small proline rich proteins

  • 1, 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 2Email author
Contributed equally
BMC Cancer201616:706

  • Received: 25 May 2015
  • Accepted: 5 July 2016
  • Published:
Open Peer Review reports



We previously described several abnormally expressed long non-coding RNA (lncRNA) in tong squamous cell carcinomas (TSCCs) that might be associated with tumor progression. In the present study, we aimed to investigate the role of abnormally expressed metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) lncRNA in the metastatic potential of TSCC cells and its molecular mechanisms.


Expression levels of MALAT-1 lncRNA were examined via quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in 127 TSCC samples as well as paired adjacent normal tissues and lymph node metastases (if exist). Lentiviral vectors expressing short hairpin RNA (shRNA) were used to knock down the expression of MALAT1 gene in two TSCC cell lines (CAL27 and SCC-25) with relatively higher MALAT-1 expression. Proliferational ability of the TSCC cells was analyzed using water soluble tetrazolium-1 (WST-1) assay. Metastatic abilities of TSCC cells were estimated in-vitro and in-vivo. We also performed a microarray-based screen to identify the genes influenced by MALAT-1 alteration, which were validated by real-time PCR analysis.


Expression of MALAT-1 lncRNA was enhanced in TSCCs, especially in those with lymph node metastasis (LNM). Knockdown (KD) of MALAT-1 lncRNA in TSCC cells led to impaired migration and proliferation ability in-vitro and fewer metastases in-vivo. DNA microarray analysis showed that several members of small proline rich proteins (SPRR) were up-regulated by KD of MALAT-1 lncRNA in TSCC cells. SPRR2A over-expression could impair distant metastasis of TSCC cells in-vivo.


Enhanced expression of MALAT-1 is associated with the growth and metastatic potential of TSCCs. Knock down of MALAT-1 in TSCCs leads to the up-regulation of certain SPRR proteins, which influenced the distant metastasis of TSCC cells.


  • Tongue squamous cell cancer
  • Long non-coding RNA
  • MALAT-1
  • Cancer metastasis


Oral cancer is the third most common cancer in developing nations and the sixth most common cancer worldwide [1, 2]. Squamous cell carcinoma is the most common oral cancer and frequently involves the tongue [35]. Although tongue squamous cell carcinoma (TSCC) can be cured with proper treatment when detected early, patients who have had TSCC have a high risk of developing secondary and/or recurrent tumors in the surrounding area, a phenomenon called field effect. Once tumor cells spread to the lymph nodes, the overall mortality rate is high and the 5-year overall survival rate does not exceed 50 % [68].

Long non-coding RNAs (lncRNAs, pseudogenes and circRNAs) have recently come into light as powerful players in cancer pathogenesis and it is becoming increasingly clear that they have the potential of greatly contributing to the spread and success of personalized cancer medicine [9, 10]. In our previous study, we identified several lncRNAs that might be associated with the progression of TSCCs in a certain number of TSCC cases, which includes MALAT-1 [11]. MALAT-1 is a novel large, noncoding RNA. The MALAT-1 gene, also known as the NEAT2 gene, is found on chromosome 11q13 and is well- conserved among mammalian species [12]. The MALAT-1 transcript is widely expressed in normal human and mouse tissue, has been shown to localize to the nucleus and its 3′ end can be processed to yield a tRNA-like cytoplasmic RNA. MALAT-1 has been shown to be a potentially generic marker for epithelial carcinomas and is greatly up-regulated in lung adenocarcinoma metastasis [13], endometrial stromal sarcoma of the uterus [14], non-hepatic human carcinomas [15] and was recently reported to be overexpressed in placenta previa and to play a role in trophoblast invasion regulation [16].

In the present study, we enrolled additional TSCC patients and examined the expression levels of MALAT-1 in all the collected samples. We explored the correlation between the MALAT-1 lncRNA expression and cancer metastasis. We also aimed to find out the differentially expressed genes between MALAT-1 knockdown and control cells by DNA microarray analysis. We found that the expression of small proline-rich protein 2A (SPRR2A) were negatively regulated by MALAT-1 expression and had an influence on cancer metastasis in vivo.


Patients and tissue collection

This study was approved by Ethics Committee of Peking University Health Science Center (IRB00001053-08043). TSCC samples were obtained from 127 patients of the Department of Oral & Maxillofacial Surgery, Shenzhen Hospital, Peking University. A summary of cohort characteristics was listed in Table 1. A detailed description of tumor characteristics was listed in Additional file 1: Table S1. Adjacent normal mucosa tissues located at least 1.5 cm far from the macroscopically unaffected margins of the tumor were defined as normal controls. All the TSCC samples were graded in 4 groups according to common criteria of SCC staging: Stage1 (less than 2 centimeters in size and has not spread to lymph nodes in the area; n = 23), Stage2 (more than 2 cm in size, but less than 4 cm, and has not spread to lymph nodes in the area; n = 55), Stage3 (more than 4 cm in size/ has spread to only one lymph node on the same side of the neck as the cancer; n = 38), Stage4 (has spread to tissues around the lip and oral cavity/ has spread to more than one lymph node on the same side of the neck as the cancer, to lymph nodes on one or both sides of the neck, or to any lymph node that measures more than 6 cm/ has spread to other parts of the body, n = 11). The TSCC tissues were collected from patients undergoing surgical excision. Matched samples of TSCC (n = 127) and normal oral squamous cell mucosa (n = 127) were subjected to real-time PCR analysis. All patients were informed about the aims of specimen collection and gave signed written consent in accordance with the ethical guidelines of Peking University.
Table 1

Summary of the cohort characteristics









Average age



23 ~ 75

Tumor Location



Lateral margin


Inferior surface




Around tongue tip


Lymph node metastasis (LNM)

With LNM


Without LNM


RNA extraction and real-time PCR

Total RNA was isolated from tissues by using a AxyPrepTM Blood Total RNA MiniPrep Kit (Axygen, US) according to the manufacturer’s instruction. First strand cDNA was synthesized with a RevertAidTM First Stand cDNA Synthesis Kit (Fermentas, US) using random hexamar primer. Quantitative PCR was performed through BioRad Chromo4 real-time PCR system. The primer sets for amplifying MALAT-1 and other related genes were listed in Table 2. Since “housekeeping” gene may have differential expression in the tissue types being evaluated [17], we compared the expression of 16 reference genes in 30 paired TSCC, ANT and LNM samples (Additional file 2: Figure S1). The sequences of the selected reference genes were listed in the Additional file 1: Table S2. We selected ACTB as the reference gene in analyzing the results. At the end point of PCR cycles, melt curves were made to check product purity. The level of MALAT-1 was expressed as a ratio relative to the β-actin mRNA in each sample. Exploratory data analysis using box plot was applied to visually identify the expression level of target mRNA.
Table 2

Primer sets used for amplifying the fragment of lncRNA transcripts and control






















Cell culture

Human tongue squamous cell carcinoma cell line CAL 27 and SCC-25 (CRL-2095™ & CRL-1628™) was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) where they were characterized by mycoplasma detection, DNA -Fingerprinting, isozyme detection and cell vitality detection. These cell lines were purchased in August 2012 and immediately expanded and frozen so that they could be restarted every 3 to 4 months from a frozen vial of the same batch of cells. CAL 27 and SCC-25 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, US) supplemented with 10 % fetal bovine serum (PAA) and 1 % penicillin/ streptomycin (Life Technologies Inc., US).

MALAT-1 knockdown by lentiviruses

To generate lentiviruses expressing MALAT-1 shRNA and control shRNAs, HEK293T cells grown on 10 cm dish were transfected with 6 μg of MALAT-1 shRNAs (cloned in PLKO.1) or control vector, 6 μg of pREV, 6 μg of pGag/Pol, and 2 μg of pVSVg. 12 h after transfection, cells were cultured with DMEM medium containing 20 % FBS for an additional 36 h. The culture medium containing lentivirus particles was centrifuged at 10000 × g for 2 min and then used for infection. 24 h after infection, cells were cultured with fresh medium for another 24 h, followed with further experiment. The knockdown efficiency was evaluated by real-time PCR analysis. The shRNA sequences targeting MALAT-1 are “ATG GAG GTA TGA CAT ATA AT” and “GGG AGT TAC TTG CCA ACT TG” [18].

Cell proliferation assay

Cell proliferation was measured by Cell Proliferation Reagent WST-1 (Roche, USA) as introduced previously [19]. Cells were counted and plated in 96-well culture plates (1 × 103 per well); WST-1 assay measuring the activity of mitochondrial dehydrogenases was performed following the manufacturer’s instructions at 0-, 1-, 2-, 3-, and 4-day time points.

Cell migration assay

Migration assays were performed using 24-well Trans-well units with 8 mm pore size polycarbonate inserts (BD Biosciences, US). Trans-wells were coated overnight with 10 mg/ml of fibronectin in PBS at 48 °C, followed by incubation with 1 % BSA for 1 h at 37 °C. The SCC-25 and CAL27 cells transfected with shRNA (MALAT-1 shRNA) or plasmids (SPRR expression vectors and mock vectors) were detached with trypsin/EDTA, washed once with DMEM containing 10 % FBS, and re-suspended in DMEM containing 1 % FBS at 2 × 105 cells/ml. Aliquots (100 microliters) of cell suspensions were directly added to the upper side of each chamber. Following incubation for 12 h, the cells on the upper side of the membrane were removed, whereas the cells that migrated to the underside were fixed with 3 % formaldehyde and stained with 0.3 % crystal violet for 10 min. The number of cells on the underside of the membrane was counted in five different fields with a light microscope at 100×, and the mean and SD was calculated from three independent experiments.

DNA microarray

After washing the cells with 50 mM potassium phosphate buffer (pH 7.4), the total RNA of each sample was extracted by RNeasy Mini Kit (Qiagen, US). The procedure for the extraction of the total RNA was according to the manufacturer’s instruction. The quality of the extracted RNA was confirmed with Bioanalyzer 2100 (Agilent Technologies, US). GeneChip(R) arrays (Affymetrix) were used as the DNA microarrays. DNA microarray analysis was performed with Bio Matrix Research. Statistical analysis after data acquisition and normalization of expression data was performed using GeneSpring (Agilent Technologies, US). For the pathway- or function-based category classification, the Munich Information Center for Protein Sequence (MIPS) was used.

Western blotting

Cells were washed with PBS and lysed in a buffer containing 50 mM Tris-HCl (pH 6.8), 2 % SDS, 10 % glycerol, phosphatase inhibitors (100 mM Na3VO4, 10 mM NaF) and protease inhibitor (1 mM PMSF). Equal amounts of protein were loaded on a SDS-PAGE and transferred to PVDF membrane. After blocking with 5 % non-fat milk in TBS-T (containing 0.1 % Tween-20), the membranes were incubated with specific primary antibodies, followed by HRP-conjugated secondary antibodies. Proteins were visualized by fluorography using an enhanced chemiluminescence system. Antibodies for SPRR1B, 2A (Abcam, US), 2E (Abnova, US) and β-actin (Sangon,Shanghai, China) were purchased as the primary antibodies for the approach.

Establishment of the SCC metastases animal model in nude mice

The animal experiments were approved by the Ethics Committee of Peking University Health Science Center (IRB00001053-09028). Six-week-old male nude mice (Zi Guang Laboratory Animal Technology Co. Ltd., Guangdong, China) were placed under general anesthesia with 1 % pentobarbital sodium (Sigma). SCC-25/CAL 27 cells (5 × 106) were injected subcutaneously (15 mice each group, and additional 15 mice for CAL27-Mock and CAL27-MALAT1KD cells). Metastasis was assayed by gross examination at autopsy and by PCR for Alu sequences in various organs. Control cells including SCC-25 and CAL27 cells caused grossly evident metastasis within the first 8 weeks and all animals were sacrificed at this time point. On the contrary, mice receiving MALAT-1 shRNA-transfectants were healthy at 8 weeks, but several were sacrificed for comparison, while the remaining mice were followed for an additional 4 weeks to determine if metastatic tumors developed. The volume of xenograft was calculated as v = 3/4πab2 (a = length, b = width). The average volume of the xenografts at sacrifice were listed in the Additional file 1: Table S3. Grossly obvious tumors and metastases were dissected and fixed immediately with 4 % paraformaldehyde for pathological analysis (Some of the animal models as well as metastases were shown in the Additional file 3: Figure S2).

Plasmids and transfection

The cloned SPRR1B & 2A cDNA fragment were inserted into pcDNA3.1 expression vector to construct the expression vectors. To produce stable transfectants, pcDNA-SPRR1B & 2A as well as mock plasmids were stably transfected into the CAL27/SCC25 line using Lipofectamine 2000 reagent (LF2000, Invitrogen, Carlsbad, CA) according to the manufacturer’s recommendations. Selection was performed via the addition of 1 mg/ml G418. The transfectants from the backbone vector and pcDNA3-SPRR1B/2A were designated as mock-CAL27/SCC25 and SPRR1B/2A-CAL27/SCC25, respectively.

Statistical analysis

GraphPad Prism software (Version 5.0) was used to analyze the obtained data. Results of the MALAT-1 lncRNA expression for paired TSCC and ANT samples or paired TSCC and local lymph-node metastasis were compared using paired t-test. Results of the MALAT-1 lncRNA expression for different TSCC groups were compared using non-parametric Mann-Whitney test. Data of in-vitro experiments were analyzed using the chi-square test or Fisher exact test. Differences of the metastasis between different groups of mouse models were analyzed using Chi-square test. P-values less than 0.05 were considered statistically significant.


Enhanced expression of MALAT-1 lncRNA correlates with lymph node metastasis in TSCCs

As a complementary experiment for the previous study, we examined the expression of MALAT-1 lncRNA in all the collected TSCC samples (n = 127), paired adjacent normal tissues (ANTs) and lymph node metastases (n = 59) in the present study. As shown in Fig. 1a, the expression levels of MALAT-1 lncRNA increased significantly in TSCCs compared to paired ANTs. In TSCC tissues with lymph node metastasis (LNM), the expression levels of MALAT-1 lncRNA were statistically higher than those without LNM (Fig. 1b). On the other hand, the differences were less significant between paired primary tumor and LNMs (n = 59, Fig. 1c).
Fig. 1
Fig. 1

Enhanced expression of MALAT-1 lncRNA in TSCC. Real-time PCR assay was carried out as described under Methods Section and the results were obtained from indicated group of samples. a Scatter plot illustrated the relative expression of MALAT-1 as a ratio of lncRNA to β-actin mRNA in each sample; b Scatter plot illustrated the relative expression of MALAT-1 as a ratio of TSCC to paired ANT in the TSCCs with or without lymph node metastasis; c Scatter plot illustrated the relative expression of MALAT-1 as a ratio of lncRNA to β-actin mRNA in each sample

Knockdown of MALAT-1 lncRNA impaired migration of TSCC cells in-vitro and in-vivo

In the preliminary work, we found that the expression levels of MALAT-1 were higher in SCC25 and CAL27 lines than those in SCC-6, SCC-9 and SCC15 lines (Fig. 2a). Thus, we selected these two cells for the in-vitro studies. After MALAT-1 was knock down by lentiviruses (Fig. 2b), the cell growth were both attenuated in SCC25 and CAL27 cells (Fig. 2c). We next estimated cell migration of SCC25 and CAL27 cells using trans-well assay. It was found that the both SCC25 and CAL27 cells with impaired expression of Malat-1 migrated less effectively through trans-well membrane (Fig. 2d & e).
Fig. 2
Fig. 2

Knockdown of MALAT-1 lncRNA impaired proliferation and migration of TSCC cells in-vitro. a Expression levels of Malat-1 lncRNA were examined by real-time PCR. b After treatment of lentiviruses expressing MALAT-1 shRNA and control shRNAs, the expression levels of MALAT-1 lncRNA were examined by real-time PCR. The relative expression of Malat-1 lncRNA (as the ratio of Malat-1 lncRNA to β-actin mRNA) is illustrated as a ratio to control (cells transfected with nonsense siRNA). c WST-1 (Roche) assay measuring the activity of mitochondrial dehydrogenases was performed following the manufacturer’s instruction at 0-, 1-, 2-, 3-, 4- day time points. Error bars represent the standard deviation of the mean; d Cell migration was determined using a transwell assay as described in the Methods section. Microscopic image of migrated CAL 27 and SCC-25 cells with indicated treatments: (I) SCC25 + control shRNA; (II) SCC25 + MALAT1KD shRNA; (III) CAL27 + control shRNA; (IV) CA L27 + MALAT1KD shRNA; e Diagrams of migrating cells from the different transfectants are shown, which are from more than three independent experiments.*P < 0.05 versus control

We next tested the metastatic potential of control shRNA and MALAT-1 shRNA transfectants 8–12 weeks after subcutaneous injection as introduced in the Methods section. Decreased number of mice that developed metastasis was observed in CAL27-MALAT1KD group compared to the control group (Table 3, p < 0.05). Detailed information of organ-specific metastases was also listed in Table 3. On the other hand, the results using SCC-25 cells could hardly be analyzed due to the insufficient metastasis formation. Thus, we selected CAL27 cells for following the in-vivo experiments.
Table 3

The number of organ-specific metastasis sites in nude mice after cell plantation

Metastasis site

CAL-27-Mock (30mice/group)

CAL27-MALAT1KD (30 mice/group)

SCC-25-Mock (15mice/group)

SCC-25-MALAT1KD (15 mice/group)


0 (0 %)

0 (0 %)

0 (0 %)

0 (0 %)


5 (16.7 %)

2 (6.7 %)

1 (6.7 %)

0 (0 %)


9 (30 %)

4 (13.3 %)

2 (13.3 %)

2 (13.3 %)


4 (13.3 %)

1 (3.3 %)

0 (0 %)

0 (0 %)


3 (10 %)

0 (0 %)

0 (0 %)

0 (0 %)


14 (46.7 %)

6 (20 %)*

4 (0 %)

2 (0 %)

Local invasion

22 (73.3 %)

18 (60 %)

12 (0 %)

13 (0 %)


7 (23.3 %)

3 (10 %)

3 (13.3 %)

1 (6.7 %)

Mice with metastases

18 (60 %)

9 (30 %)*

5 (33.3 %)

2 (13.3)

*P < 0.05 V.S. CAL27-Mock group

Knockdown of MALAT-1leads to the enhanced expression of several SPRR proteins

As a non-coding RNA, MALAT-1 could not directly influence cell migrational ability. We surveyed the differentially expressed genes between MALAT-1 KD and control cells by DNA microarray analysis. Numerous genes showing significant differential expression were identified in the microarray analysis in two independent MALAT-1 KD cell lines. The down-regulated genes in MALAT-1 KD cells included genes previously implicated in extracellular matrix and cytoskeleton regulation, such as LAYN, CCT4, CTHRC1, and FHL1. Here we noticed that expressions levels of several members of SPRR family were also influenced by MALAT-1 KD (Fig. 3a), which was a novel finding.
Fig. 3
Fig. 3

Knockdown of MALAT-1 leads to the enhanced expression of SPRR proteins. a The heatmap illustrated the genes most significantly influenced by KD of MALAT-1 using microarray analysis. b & c Real-time PCR analysis was carried out to examine the mRNA expression of selected genes screened by microarray analysis;*P < 0.05 versus control; **P < 0.01 versus control. d, e & f Western blotting was performed to examine the protein levels of SPRR1B, 2A &2E in CAL 27 and SCC-25 cells; β-actin was used as control. g The histogram shows the mean ± SD of the gray scale analysis, which were obtained from 3 independent experiments each group; *P < 0.05;**P < 0.01

The qRT-PCR analysis was performed to confirm the expression level of differential expressed genes. As shown in Fig. 3b, mRNA levels of SPRR1B, SPRR2A, and SPRR2E were significantly up-regulated in MALAT-1 KD cells. The altered expression of LAYN, CCT4, CTHRC1, and FHL1 were also confirmed by qRT-PCR (Fig. 3c). We also used a Western blot to examine the protein levels of these genes. It was found that the protein levels of SPRR1B and 2A were significantly induced in MALAT-1 KD cells (Fig. 3d, e & g), while SPRR2E were slightly influenced (Fig. 3f & g).

Over-expression of SPRR2A prevents TSCC metastasis in-vivo

Previously, it was indicated that LAYN, CCT4, CTHRC1, and FHL1 gene were correlated with the migrational potential of lung cancer cells [13]. Here we wondered whether SPRRs regulated by MALAT-1 also could influence TSCC metastasis. SPRRs are a subclass of structural proteins which constitute cornified cell envelope precursors. Several studies have suggested that the SPRRs are related to increased epithelial proliferation and malignant processes. Here we first use trans-well assay to estimate the migrational/invasive abilities of TSCC cells with different expression of SPRR1B and 2A. As shown in Fig. 4a & c, SPRR2A/1B transfectants showed marked increase of protein levels in CAL27 and SCC25 cells. In-vitro studies showed that over-expression of SPRR1B and 2A slightly promoted the migration of CAL 27 cells and SCC25 cells (Fig. 4b & d) and had little effects on cell proliferation (Additional file 4: Figure S3). We next tested the metastatic potential of mock vector and SPRR2A/1B transfectants 8–12 weeks after subcutaneous injection. SPRR2A-CAL27 cells showed impaired distant metastasis compared to Mock-CAL27 cells (Table 4), while no obvious differences were observed between SPRR1B-CAL27 cell and mock cells. Thus, increased MALAT-1 expression might enhance TSCC distant metastasis partially through the down-regulation of SPRR2A.
Fig. 4
Fig. 4

SPRR2A promotes TSCC migration in-vitro. a & c Western blotting was performed to examine the protein levels of SPRR1B & 2A in the targeted cells; β-actin was used as control. b & d Cell migration was determined using a transwell assay as described Fig. 2c (the incubation time of the cells here was adjusted to 8 h to avoid high density). Diagrams of migrating cells from the different are shown, which are from more than three independent experiments.*P < 0.05 versus control

Table 4

The number of organ-specific metastasis sites in nude mice after cell plantation (15 mice/each group)

Metastasis site




























Local invasion








Mice with metastases

11 (73.3 %)

5 (33.3 %)*

12 (80 %)

*P < 0.05 V.S. Mock-CAL27 group

Discussion and conclusions

LncRNA contributes significantly to human transcriptome and is believed to play a critical role in cancer development. A previous report showed that ~60 % of the detected lncRNAs have aberrant expressions in oral premalignant lesions [20]. Previously we focused on TSCC and a series of abnormally expressed cancer-related lncRNAs were identified [11]. Here we further proved that the expression levels of MALAT-1 lncRNA were markedly elevated in TSCC, especially in TSCC with LNM. In TSCCs with LNM, increased expression of MALAT-1 lncRNA was detected in LNMs than in primary tumors. Cell growth and migration was attenuated in MALAT1-KD TSCC cells. These all indicated the potential role of MALAT-1 lncRNA in metastasis of TSCCs.

In microarray analysis, we found that MALAT-1 knockdown led to the accumulation of SPRR proteins, which was a novel finding. The SPRRs constitute cornified cell envelope precursors [21]. Several studies have suggested that the SPRRs are related to increased epithelial proliferation and malignant progression [22]. Why knockdown of MALAT-1 lncRNA would lead to the accumulation of SPRR proteins in TSCC cells? One possibility is that MALAT1 regulates gene transcription via modification of the epigenetic program. Yang et al. reports MALAT1 can facilitate the assembly of multiple co-repressors/co-activators and finds that MALAT1 alters the histone modifications on chromatin by alternating the activity of Polycomb2 protein (Pc2) [23]. In addition, MALAT1 molecule has been linked to the physical interaction with critical chromatin-modifier Polycomb Repressive Complex 2 (PRC2) to modulate the epigenetic status of target genes [24]. Hirata H. et al. [25] reports that MALAT1 directly binds to the EZH2 protein, which is a critical component of the PRC2 complex to play the methyltransferase activity of the chromatin histone modifications; similar result showed that MALAT1 binds to active chromatin sites [26]. These experimental evidences showed that MALAT1 modulates the chromatin histone methylations by binding to PRC2 complex and abolishing its methylation activity.

Another possibility goes to the direct regulation of target gene by lncRNA. Four different regulation mechanisms by lncRNAs might be involved in MALAT1-mediated modulation: (a) MALAT-1 lncRNA molecule interacts with double strand DNA and represses gene transcription; (b) MALAT-1 lncRNA fragments act as intronic siRNA to bind with mRNA and repressing mRNA translation; (c) Produce alternative splicing lncRNAs to regulate gene expression. Different isoforms from alternative splicing have different regulation activity and specificity, which regulate the gene expression with different patterns; (d) MALAT-1 lncRNA molecule interacts with basal transcriptional machinery which disrupts the transcription initiation complex and represses transcription [2729]. These need further investigation.

In the present study, over-expression of SPRR2A in TSCC cells could slightly promote cell migration in-vitro but impair distant metastasis in-vivo, which seemed to be a confusing result. A previous finding also showed that SPRR2A over-expression increases local tumor invasiveness but prevents metastasis in cholangiocarcinoma [30]. This may be explained by the irreversible epithelial-mesenchymal transition (EMT) of the SPRR2A transfectants. Progression of epithelial tumors requires temporary acquisition of mesenchymal characteristics (EMT), which allows for local invasion and hematogenous dissemination of the cancer cells. At distant sites, these cells undergo mesenchymal-epithelial transition (MET) to establish residence and form tumors that are histopathologically similar to the primary tumor. Dr. Specht et al. reported that their stable SPRR2A clones are in a permanent, irreversible mesenchymal state. In the current study, CAL27-SPRR2A cells also appeared to be plastic and have high mobility, which showed mesenchymal behavior (indicated by increased Twist protein expression in SPRR2A-CAL27 but not SPRR1B-CAL27, Additional file 5: Figure S4). Thus, impaired MET ability of SPRR2A-CAL27 might be associated with the reduced distant metastases.

In general, plausibly, our findings indicated that the expression level of MALAT-1 have the potential to indicate MALAT-1 have potential for prognostic indicator in lymph node metastasis of TSCC. MALAT-1 knockdown led to the accumulation of SPRR proteins, in which SPRR2A was shown to be associated with the distant metastasis of TSCCs. The underlying mechanisms of the regulation of SPRRs by MALAT-1 need to be extensively investigated in the future.



Metastasis-associated lung adenocarcinoma transcript 1


Tong squamous cell carcinoma


Long non-coding RNA


Quantitative reverse transcriptase polymerase chain reaction


Short hairpin RNA


Water soluble tetrazolium-1


Lymph node metastasis


Small proline rich




Munich Information Center for Protein Sequence


Adjacent normal tissue




Chaperonin containing TCP1 subunit 4


Collagen triple helix repeat containing 1


Four and a half LIM domains 1



This work was supported by National Natural Science Foundation of China (Grant No.: 81572654), Natural Science Foundation of Guangdong Province (Grant No.: s2012010010382, 2015A030313754); Shenzhen Science and Technology Plan of Basic Research Projects (Grant No.: JCYJ20140416144209741, JCYJ20130402114702120, JCYJ20140415162338806).

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Authors’ contributions

FZY examined the expression levels of MALAT-1 in TSCC samples and participated in the cell proliferation assays and signaling pathway analysis, and drafted the manuscript. ZSS & WYF carried out the immunofluorescence staining as well as the western blotting analysis. SSY and WF collected clinical TSCC samples and extracted the total RNA as well as the protein. HYH & LYX carried out the real-time PCR approaches and participated in statistical analysis. ZBY participated in cell culture and transfection and participated in a statistical analysis. ZY participated in signaling pathway analysis and helped to draft the manuscript. YHY conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work. There are no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled,“Long non-coding RNA MALAT-1 Modulates Metastatic Potential of Tongue Squamous Cell Carcinomas Partially Through the Regulation of Small Proline Rich proteins”.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The experiments using clinical samples were approved by Ethics Committee of Peking University Health Science Center (IRB00001053-08043). The animal experiments were approved by the Ethics Committee of Peking University Health Science Center (IRB00001053-09028).

Grant Sponsor

National Natural Science Foundation of China (Grant No.: 81572654); Natural Science Foundation of Guangdong Province (Grant No.: s2012010010382, 2015A030313754); Shenzhen Science and Technology Plan of Basic Research Projects (Grant No.: JCYJ20140416144209741, JCYJ20130402114702120; JCYJ20140415162338806).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Biomedical Research Institute, Shenzhen Peking University- The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong province, China
Department of Oral and Maxillofacial, Shenzhen Hospital, Peking University, Shenzhen, Guangdong Province, People’s Republic of China


  1. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent. 2001;49(1):72–82.PubMedGoogle Scholar
  2. Rosebush MS, Rao SK, Samant S, Gu W, Handorf CR, Pfeffer LM, Nosrat CA. Oral cancer: enduring characteristics and emerging trends. J Mich Dent Assoc. 2012;94(2):64–8.PubMedGoogle Scholar
  3. Kejner AE, Burch MB, Sweeny L, Rosenthal EL. Bone morphogenetic protein 6 expression in oral cavity squamous cell cancer is associated with bone invasion. Laryngoscope. 2013;123(12):3061–5.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Zygogianni AG, Kyrgias G, Karakitsos P, Psyrri A, Kouvaris J, Kelekis N, Kouloulias V. Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol. 2011;3:2.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Zhen W, Karnell LH, Hoffman HT, Funk GF, Buatti JM, Menck HR. The National Cancer Data Base report on squamous cell carcinoma of the base of tongue. Head Neck. 2004;26(8):660–74.View ArticlePubMedGoogle Scholar
  6. Cannon TL, Lai DW, Hirsch D, Delacure M, Downey A, Kerr AR, Bannan M, Andreopoulou E, Safra T, Muggia F. Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? Oncologist. 2012;17(12):1541–6.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18 F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53(5):709–15.View ArticlePubMedGoogle Scholar
  8. Trotta BM, Pease CS, Rasamny JJ, Raghavan P, Mukherjee S. Oral cavity and oropharyngeal squamous cell cancer: key imaging findings for staging and treatment planning. Radiographics. 2011;31(2):339–54.View ArticlePubMedGoogle Scholar
  9. Hauptman N, Glavac D. Long non-coding RNA in cancer. Int J Mol Sci. 2013;14(3):4655–69.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45(8):1895–910.View ArticlePubMedGoogle Scholar
  11. Fang Z, Wu L, Wang L, Yang Y, Meng Y, Yang H. Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(1):89–95.View ArticlePubMedGoogle Scholar
  12. Gutschner T, Hammerle M, Diederichs S. MALAT1 -- a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013;91(7):791–801.View ArticlePubMedGoogle Scholar
  13. Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 2010;584(22):4575–80.View ArticlePubMedGoogle Scholar
  14. Yamada K, Kano J, Tsunoda H, Yoshikawa H, Okubo C, Ishiyama T, Noguchi M. Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci. 2006;97(2):106–12.View ArticlePubMedGoogle Scholar
  15. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26(6):851–8.View ArticlePubMedGoogle Scholar
  16. Tseng JJ, Hsieh YT, Hsu SL, Chou MM. Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro. Mol Hum Reprod. 2009;15(11):725–31.View ArticlePubMedGoogle Scholar
  17. Fu LY, Jia HL, Dong QZ, Wu JC, Zhao Y, Zhou HJ, Ren N, Ye QH, Qin LX. Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses. BMC Cancer. 2009;9:49.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Fang Z, Yao W, Xiong Y, Li J, Liu L, Shi L, Zhang W, Zhang C, Nie L, Wan J. Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression. BMC Cancer. 2011;11:195. 191–111.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Gibb EA, Enfield KS, Stewart GL, Lonergan KM, Chari R, Ng RT, Zhang L, MacAulay CE, Rosin MP, Lam WL. Long non-coding RNAs are expressed in oral mucosa and altered in oral premalignant lesions. Oral Oncol. 2011;47(11):1055–61.View ArticlePubMedGoogle Scholar
  21. Carregaro F, Stefanini AC, Henrique T, Tajara EH. Study of small proline-rich proteins (SPRRs) in health and disease: a review of the literature. Arch Dermatol Res. 2013;305(10):857–66.View ArticlePubMedGoogle Scholar
  22. Tesfaigzi J, Carlson DM. Expression, regulation, and function of the SPR family of proteins. A review. Cell Biochem Biophys. 1999;30(2):243–65.View ArticlePubMedGoogle Scholar
  23. Yang F, Yi F, Han X, Du Q, Liang Z. MALAT-1 interacts with hnRNP C in cell cycle regulation. FEBS Lett. 2013;587(19):3175–81.View ArticlePubMedGoogle Scholar
  24. Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription. 2014;5(4):e944014.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, Ishii N, Dahiya R. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res. 2015;75(7):1322–31.View ArticlePubMedGoogle Scholar
  26. West JA, Davis CP, Sunwoo H, Simon MD, Sadreyev RI, Wang PI, Tolstorukov MY, Kingston RE. The long noncoding RNAs NEAT1 and MALAT1 bind active chromatin sites. Mol Cell. 2014;55(5):791–802.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Ernst C, Morton CC. Identification and function of long non-coding RNA. Front Cell Neurosci. 2013;7:168.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Kornienko AE, Guenzl PM, Barlow DP, Pauler FM. Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013;11:59.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Wierzbicki AT. The role of long non-coding RNA in transcriptional gene silencing. Curr Opin Plant Biol. 2012;15(5):517–22.View ArticlePubMedGoogle Scholar
  30. Specht S, Isse K, Nozaki I, Lunz 3rd JG, Demetris AJ. SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. Clin Exp Metastasis. 2013;30(7):877–90.View ArticlePubMedGoogle Scholar


© The Author(s). 2016